Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Home »
Pharmacology » Ion Channels » Ligand-gated Ion Channels » Glutamate (Ionotropic) Receptors » NMDA Receptors » Ro 04-5595 hydrochloride
Ro 04-5595 hydrochlorideCat. No. 2005 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 1-[2-(4-Chlorophenyl)ethyl]-1,2,3,4-tetrahydro-6-methoxy-2-methyl-7-isoquinolinol hydrochloride |
Biological Activity
Selective antagonist for NR2B-containing NMDA receptors (Ki = 31 nM).Certificate of Analysis / Safety Data Sheet
Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet
References
Mutel et al (1998) In vitro binding properties in rat brain of [3H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J.Neurochem. 70 214.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Ro 04-5595 hydrochloride, supplier, Selective, NR2B, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Ro04-5595, hydrochloride
Quick Order
Find multiple products by catalog number
New Products in this Area
PF 4778574
Positive allosteric modulator of AMPA
CMPDAPositive allosteric modulator of GluA2 receptors
Sign-up for new product e-alerts
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK








